Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 12, 2015, Pages 1696-1704

  Tu, Thomas ^a,b   Calabro, Sarah R ^a,b   Lee, Aimei ^a,b   Maczurek, Annette E ^a,b   Budzinska, Magdalena A ^a,b   Warner, Fiona J ^a,b   Mclennan, Susan V ^b,c   Shackel, Nicholas A ^a,b,c  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cell and molecular biology; EMMPRIN; Hepatic inflammation; Hepatology; Liver fibrogenesis; Liver immunobiology; Liver regeneration; Matrix metalloproteinases; Stellate cell biology

Indexed keywords

CELL DEATH; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASES; LIVER REGENERATION; PATHOLOGY; PHYSIOLOGY;

CELL DEATH; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER REGENERATION;

EID: 84954461188     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13065     Document Type: Review

References (75)

1. WHO. Global health estimates 2014 summary tables: deaths by cause, age and sex, 2000-2012. In: WHO, ed. Disease and Injury Regional Mortality Estimates. Geneva, Switzerland: WHO 2014: http://www.who.int/healthinfo/global_burden_disease/estimates/en/.
2. Roskams T, Desmet VJ, Verslype C. Development, structure and function of the liver. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween's Pathology of the Liver. 5th edn. Philidelphia, PA, USA: Churchill Livingstone Elsevier, 2007; 1-74.
3. Kisseleva T, Cong M, Paik Y et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2012; 109: 9448-53.
4. Makino H, Togo S, Kubota T et al. A good model of hepatic failure after excessive hepatectomy in mice. J. Surg. Res. 2005; 127: 171-6.
5. Colletti LM, Green ME, Burdick MD, Strieter RM. The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 2000; 31: 435-45.
6. Prakoso E, Tirnitz-Parker JE, Clouston AD et al. Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. Liver Transpl. 2014; 20: 1508-19.
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006; 45: 529-38.
8. Crawford JM. Basic mechanisms in hepatopathology. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween's Pathology of the Liver. 5th edn. Philidelphia, PA, USA: Churchill Livingstone Elsevier, 2007; 75-117.
9. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J. Clin. Pathol.. 1978; 31: 395-414.
10. Xu B, Hu DC, Rosenberg DM et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J. Gastroenterol. Hepatol. 2003; 18: 1345-52.
11. Lin X, Robinson NJ, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J. Gastroenterol. Hepatol. 2005; 20: 833-43.
12. Issa R, Williams E, Trim N et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-57.
13. Soliman GM, Mohammed KA, Taha A, Barrak AA. The role of plasma transforming growth factor beta-1 in the development of fibrosis in patient with HCV related steatohepatitis. J. Egypt. Soc. Parasitol. 2010; 40: 759-72.
14. Shih PH, Hwang SL, Yeh CT, Yen GC. Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways. J. Agric. Food Chem. 2012; 60: 2924-33.
15. Okada K, Shoda J, Taguchi K, et al. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem. Biophys. Res. Commun. 2009; 389: 431-6.
16. Guicciardi ME, Malhi H, Mott JL, Gores GJ. Apoptosis and necrosis in the liver. Comp. Physiol. 2013; 3: 977-1010.
17. Roychowdhury S, McMullen MR, Pisano SG, Liu X, Nagy LE. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013; 57: 1773-83.
18. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2014; 346: 17-23.
19. Gautheron J, Vucur M, Reisinger F et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 2014; 6: 1062-74.
20. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-72.
21. Szabo G, Csak T. Inflammasomes in liver diseases. J. Hepatol. 2012; 57: 642-54.
22. Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994; 263: 1149-52.
23. Van Thiel DH, Gavaler JS, Kam I et al. Rapid growth of an intact human liver transplanted into a recipient larger than the donor. Gastroenterology 1987; 93: 1414-9.
24. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-53.
25. Rogers AE, Shaka JA, Pechet G, Macdonald RA. Regeneration of the liver. Absence of a "humoral factor" affecting hepatic regeneration in parabiotic rats. Am. J. Pathol. 1961; 39: 561-78.
26. Tamori Y, Deng WM. Compensatory cellular hypertrophy: the other strategy for tissue homeostasis. Trends Cell Biol. 2014; 24: 230-7.
27. Sun L, Chow PK, Fook-Chong SM, Chew M, Aw SE, Soo KC. Liver regeneration after partial hepatectomy is non-uniform: flow cytometric bromodeoxyuridine incorporation and cell cycle studies in a porcine model. Res. Exp. Med. (Berl). 1999; 198: 229-36.
28. Yanger K, Knigin D, Zong Y et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell Stem Cell 2014; 15: 340-9.
29. Lichtinghagen R, Bahr MJ, Wehmeier M et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin. Sci. (Lond.) 2003; 105: 373-82.
30. Kossakowska AE, Edwards DR, Lee SS et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am. J. Pathol. 1998; 153: 1895-902.
31. Garciade Leon Mdel C, Montfort I, Tello Montes E et al. Hepatocyte production of modulators of extracellular liver matrix in normal and cirrhotic rat liver. Exp. Mol. Pathol. 2006; 80: 97-108.
32. Martinez-Hernandez A, Delgado FM, Amenta PS. The extracellular matrix in hepatic regeneration. Localization of collagen types I, III, IV, laminin, and fibronectin. Lab. Invest. 1991; 64: 157-66.
33. Bianchi FB, Biagini G, Ballardini G et al. Basement membrane production by hepatocytes in chronic liver disease. Hepatology 1984; 4: 1167-72.
34. Nakatsukasa H, Nagy P, Evarts RP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J. Clin. Invest. 1990; 85: 1833-43.
35. Milani S, Herbst H, Schuppan D, Surrenti C, Riecken EO, Stein H. Cellular localization of type I, III and IV procollagen gene transcripts in normal and fibrotic human liver. Am. J. Pathol. 1990; 137: 59-70.
36. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J. Clinic. Investigat. 1990; 86: 1641-8.
37. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 8681-5.
38. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm. Allergy Drug Targets 2011; 10: 509-36.
39. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model. Mech. 2014; 7: 193-203.
40. Calabro SR, Maczurek AE, Morgan AJ et al. Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS One 2014; 9: e90571.
41. Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 2002; 277: 11069-76.
42. Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-808.
43. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
44. Schiff ER, Lee SS, Chao YC et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9: 274-6.
45. Ogata I, Mochida S, Tomiya T, Fujiwara K. Minor contribution of hepatocytes to collagen production in normal and early fibrotic rat livers. Hepatology 1991; 14: 361-7.
46. Theret N, Musso O, L'Helgoualc'h A, Clement B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am. J. Pathol. 1997; 150: 51-8.
47. Theret N, Musso O, L'Helgoualc'h A, Campion JP, Clement B. Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers. Am. J. Pathol. 1998; 153: 945-54.
48. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001; 49: 565-76.
49. Grzelak CA, Martelotto LG, Sigglekow ND et al. The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury. J. Hepatol. 2014; 60: 143-51.
50. Ramm GA, Shepherd RW, Hoskins AC et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009; 49: 533-44.
51. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol. Res. 2003; 26: 1-9.
52. Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J. Clin. Invest. 1995; 96: 447-55.
53. Kimura M, Ogihara M. Transforming growth factor-beta1 inhibits the growth of primary adult rat hepatocyte cultures by increasing cAMP levels. Eur. J. Pharmacol. 1999; 386: 271-7.
54. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR et al. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab. Invest. 2008; 88: 1090-100.
55. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin. Sci. (Lond.) 2007; 113: 109-18.
56. Bataller R, Gabele E, Schoonhoven R et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 285: G642-51.
57. Apolinario A, Majano PL, Alvarez-Perez E et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am. J. Gastroenterol. 2002; 97: 2861-70.
58. Herkel J, Jagemann B, Wiegard C et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology 2003; 37: 1079-85.
59. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J. Autoimmun. 2010; 34: 1-6.
60. Tay SS, Wong YC, McDonald DM et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc. Natl. Acad. Sci. U. S. A. 2014; 111: E2540-9.
61. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000; 279: G245-9.
62. Herbst H, Wege T, Milani S et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am. J. Pathol. 1997; 150: 1647-59.
63. Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, Arthur MJ. Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology 1995; 22: 304-15.
64. Benyon RC, Hovell CJ, Da Gaca M, Jones EH, Iredale JP, Arthur MJ. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999; 30: 977-86.
65. Geisler S, Lichtinghagen R, Boker KH, Veh RW. Differential distribution of five members of the matrix metalloproteinase family and one inhibitor (TIMP-1) in human liver and skin. Cell Tissue Res. 1997; 289: 173-83.
66. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J. Hepatol. 1999; 30: 48-60.
67. Lo L, McLennan SV, Williams PF et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J. Hepatol. 2011; 55: 435-44.
68. Royo F, Schlangen K, Palomo L et al. Transcriptome of extracellular vesicles released by hepatocytes. PLoS One 2013; 8: e68693.
69. Povero D, Eguchi A, Li H et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 2014; 9: e113651.
70. Zhang W, Zhao P, Xu XL et al. Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One 2013; 8: e67268.
71. Sahin H, Borkham-Kamphorst E, Kuppe C et al. Chemokine CXCL9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012; 55: 1610-9.
72. Ren X, Kennedy A, Colletti LM. CXC chemokine expression after stimulation with interferon-gamma in primary rat hepatocytes in culture. Shock 2002; 17: 513-20.
73. Nishioji K, Okanoue T, Itoh Y et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin. Exp. Immunol. 2001; 123: 271-9.
74. Harvey CE, Post JJ, Palladinetti P et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 2003; 74: 360-9.
75. Hammerich L, Bangen JM, Govaere O et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 2014; 59: 630-42.